This is the authors' abstract. We don't add key points for this paper.
The PROGENSA PCA3 assay can aid in guiding biopsy decisions. It is superior to total prostate specific antigen, prostate specific antigen density and %free prostate specific antigen in predicting initial biopsy outcome, and may be indicative of prostate cancer aggressiveness.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Taille et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: